XTALPI (02228) reaches a strategic cooperation with a well-known international pharmaceutical company, surpassing 400 million US dollars in AI drug discovery, targeting GPCR targets for oral new drugs.

XTALPI (02228) announced that the company's board of directors is pleased to announce a strategic partnership with an internationally renowned biopharmaceutical company. The two parties will jointly develop an innovative oral small molecule drug with "Best in-Class" potential targeting a GPCR (G-protein coupled receptor) target. This agreement is based on a rigorous and successful pilot phase, during which XTALPI integrated quantum physics and AI algorithms to achieve breakthrough hit rates, confirming the platform's capability to handle such complex metabolic targets. According to the agreement, the partner will make an initial payment to XTALPI and cover all early-stage development costs. XTALPI will also receive milestone payments for preclinical, clinical, and commercial achievements, as well as future sales royalties, with a total potential value of over $400 million. This partnership model, which deeply links near-term research revenue with long-term pipeline asset value, effectively reduces the cost and risk of XTALPI's involvement in high barrier target research, while also securing a high return potential for blockbuster drugs. This partnership not only reflects the profound trust of leading pharmaceutical companies in XTALPI's research strength, but also reaffirms XTALPI's competitive advantage and sustainable growth potential in tackling difficult-to-treat and high-value targets. Breaking through the barrier of complex GPCR small molecule "difficult-to-treat" drugs. The GPCR target focused on in this collaboration exists in a dynamic equilibrium of multiple subtypes, making it extremely difficult for small molecules to accurately target its natural binding pocket. There have been no publicly reported small molecules in the world that bind to this target in a co-crystal structure. Traditional high-throughput screening (HTS) is unable to simultaneously optimize core metrics such as activity, selectivity, and pharmacokinetic properties to generate competitive molecular candidates, and existing small molecule pipeline projects are in the early stages of clinical development. Facing this structural biology challenge, XTALPI has significantly improved the efficiency and precision of hit compound discovery using its advanced computational drug development platform, transitioning from traditional "needle in a haystack" to "intelligent navigation." The platform has demonstrated outstanding innovation breakthroughs and delivery capabilities in lead compound projects for customers. Decoding conformational dynamics. Leveraging advanced quantum physics models and AI algorithms, XTALPI efficiently screened a commercial compound library of billions in size, and then used its proprietary XFEP (Free Energy Perturbation) platform to accurately predict molecular affinity. Scaling up research and development through closed-loop AI and Siasun Robot & Automation engine. Upon entering the comprehensive collaboration phase, XTALPI will fully utilize its rational structure drug design platform. Through seamless integration of quantum physics, generative AI, and large-scale automated chemical synthesis coordinated by the Multi-AI-Agent system, XTALPI will drive rapid Design-Synthesis-Test-Analysis (DMTA) cycles. The automated laboratory infrastructure bridges the historical gap between computational design and wet laboratory synthesis and validation, continuously yielding new candidate drugs optimized for high activity and ideal ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties. Ultimately, this approach aims to significantly expand the potential drug chemistry space and shorten the development cycle, accelerating the translation of cutting-edge computational breakthroughs into substantial clinical assets benefiting patients globally.